Literature DB >> 34676435

Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting.

Fernanda Rodrigues Mendes1,2, Wellington Fernandes da Silva1,2, Raphael da Costa Bandeira de Melo1,3, Douglas Rafaele Almeida Silveira2,4, Elvira Deolinda Rodrigues Pereira Velloso1,3, Vanderson Rocha1,2,3, Eduardo Magalhaes Rego5,6,7.   

Abstract

Despite advances in supportive measures, acute myeloid leukemia (AML) remission induction still has a high mortality rate in real-world studies as compared to prospective reports. We analyzed data from 206 AML adult patients treated with conventional chemotherapy. The primary endpoint was the 60-day mortality rate, aiming to find risk factors and to examine the role of anti-infection prophylaxis. The 60-day mortality rate was 26%, raising to 41% among those older than 60 years. Complete response was documented at the end of induction in 49%. The final survival model showed that age > 60 years (HR 3.2), Gram-negative colonization (HR 3), monocytic AML (HR 1.8), C-reactive protein (CRP) > 15 mg/dL (HR 10), and an adverse risk in the genetic stratification (HR 3) were associated with induction death. Multidrug-resistant bacteria colonization, thrombosis, and AKI were documented in 71%, 12%, and 66% of the cohort, respectively. Antibacterial and antifungal prophylaxis did not improve outcomes in this study. Our report corroborated the higher mortality during AML induction compared to real-world data from the USA and Europe. In line with other publications, age and cytogenetic stratification influenced early death in this cohort. Noticeably, Gram-negative colonization, monocytic AML, and CRP were also significant to early mortality.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Acute myeloid leukemia; Early death; Induction remission; Intensive chemotherapy

Mesh:

Substances:

Year:  2021        PMID: 34676435     DOI: 10.1007/s00277-021-04687-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  28 in total

1.  Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.

Authors:  Mariana Tereza de Lira Benicio; Ana Flávia Tibúrcio Ribeiro; Andre D Américo; Felipe M Furtado; Ana B Glória; Aleide S Lima; Silvana M Santos; Sandra G Xavier; Antonio R Lucena-Araujo; Evandro M Fagundes; Eduardo M Rego
Journal:  Leuk Res       Date:  2017-07-24       Impact factor: 3.156

2.  How I treat acute myeloid leukemia in the era of new drugs.

Authors:  Courtney D DiNardo; Andrew H Wei
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

3.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

Authors:  J W Yates; H J Wallace; R R Ellison; J F Holland
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

4.  Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia.

Authors:  Douglas R A Silveira; Lynn Quek; Itamar S Santos; Anna Corby; Juan L Coelho-Silva; Diego A Pereira-Martins; Grant Vallance; Benjamin Brown; Luciana Nardinelli; Wellington F Silva; Elvira D R P Velloso; Antonio R Lucena-Araujo; Fabiola Traina; Andy Peniket; Paresh Vyas; Eduardo M Rego; Israel Bendit; Vanderson Rocha
Journal:  Blood Adv       Date:  2020-05-26

5.  De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center.

Authors:  Evandro M Fagundes; Vanderson Rocha; Ana Beatriz F Glória; Nelma Cristina D Clementino; José S Quintão; João Paulo O Guimarães; Enio Roberto P Pedroso; Marcos B Viana
Journal:  Leuk Lymphoma       Date:  2006-08

6.  Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.

Authors:  Amer M Zeidan; Nikolai A Podoltsev; Xiaoyi Wang; Chi Zhang; Jan Philipp Bewersdorf; Rory M Shallis; Scott F Huntington; Natalia Neparidze; Smith Giri; Steven D Gore; Amy J Davidoff; Xiaomei Ma; Rong Wang
Journal:  Blood Adv       Date:  2020-04-28

7.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Authors:  Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

8.  Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis.

Authors:  Mary-Elizabeth M Percival; Li Tao; Bruno C Medeiros; Christina A Clarke
Journal:  Cancer       Date:  2015-03-04       Impact factor: 6.860

9.  Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.

Authors:  Gwendolyn Ho; Brian A Jonas; Qian Li; Ann Brunson; Ted Wun; Theresa H M Keegan
Journal:  Br J Haematol       Date:  2017-04-17       Impact factor: 6.998

10.  A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?

Authors:  Douglas R A Silveira; Juan L Coelho-Silva; Wellington F Silva; Grant Vallance; Diego A Pereira-Martins; Maria I A Madeira; Lorena L Figueredo-Pontes; Elvira D R P Velloso; Belinda P Simões; Andy Peniket; Robert Danby; Eduardo M Rego; Paresh Vyas; Fabiola Traina; Israel Bendit; Lynn Quek; Vanderson Rocha
Journal:  Leuk Lymphoma       Date:  2020-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.